Goodwin (JD Supra South Korea)
3 results for Goodwin (JD Supra South Korea)
-
Phase 1 Clinical Trial of Aflibercept (Eylea®) Biosimilar Completed by Alteogen
Alteogen recently announced that it has successfully completed a Phase 1 clinical trial for its Eylea® biosimilar, ALT-L9. Alteogen conducted the clinical trials in South Korea, where its headquarters are located.
-
South Korea’s Biosimilars Industry Poised to Grow Domestically and Abroad
According to the Korea Pharmaceutical Manufacturers Association, the biosimilars market in South Korea will grow to 150 billion won (~$130 million) by 2019, nearly doubling in size from its 2013 value. Six biosimilars have been approved in South Korea since 2012, and dozens of other biosimilars are currently in the development pipeline.
-
LG Life Sciences Begins Phase III Trials for Humira Biosimilar
LG Life Sciences recently announced the start of phase III clinical trials for its Humira® (adalimumab) biosimilar in South Korea. The clinical trials will test the effectiveness of the biosimilar on rheumatoid arthritis patients who have shown negative responses to the chemotherapy drug methotrexate. The trials will also compare the efficacy and safety of the biosimilar to Humira®.